AGY Therapeutics

About:

A South San Francisco, Calif .-based biopharmaceutical company

Website: http://www.agyinc.com/

Top Investors: Alta Partners, JAFCO Asia, Novartis Venture Fund, JAFCO, Forward Ventures

Description:

AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

Total Funding Amount:

$22M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

San Francisco, California, United States

Founded Date:

1998-01-01

Founders:

Number of Employees:

51-100

Last Funding Date:

2004-08-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai